Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

被引：38
|
作者：
Garcia, Jacqueline S.
Wei, Andrew H.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nolte, Florian
Jurcic, Joseph G.
Jacoby, Meagan A.
Hong, Wan-Jen
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Tong, Bo
Hogdal, Leah
Kamalakar, Rajesh
Hutti, Jessica E.
Kye, Steve
Garcia-Manero, Guillermo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139492
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Garcia, Jacqueline Suen
    Fenaux, Pierre
    Platzbecker, Uwe
    Miyazaki, Yasushi
    Xiao, Zhi-Jian
    Zhou, Ying
    Naqvi, Kiran
    Kye, Steve
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes
    Zeidner, Joshua F.
    Mazerolle, Flora
    Bell, Jill A.
    Cain, Lauren E.
    Faller, Douglas V.
    Dalal, Mehul
    Regnault, Antoine
    Fram, Robert J.
    BLOOD, 2020, 136
  • [43] Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study
    Amitai, Irina
    Geddes, Michelle
    Zhu, Nancy
    Keating, Mary-Margaret
    Sabloff, Mitchell
    Christou, Grace
    Leber, Brian
    Khalaf, Dina
    Leitch, Heather A.
    St-Hilaire, Eve
    Finn, Nicholas
    Shamy, April
    Yee, Karen
    Storring, John
    Nevill, Thomas
    Delage, Robert
    Elemary, Mohamed
    Banerji, Versha
    Chodirker, Lisa
    Mozessohn, Lee
    Parmentier, Anne
    Siddiqui, Mohammed
    Mamedov, Alexandre
    Zhang, Liying
    Buckstein, Rena
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (02) : 319 - 324
  • [44] Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
    Daver, Naval
    Aribi, Ahmed
    Montesinos, Pau
    Roboz, Gail J.
    Wang, Eunice S.
    Walter, Roland B.
    Jeyakumar, Deepa
    DeAngelo, Daniel J.
    Erba, Harry P.
    Advani, Anjali
    Burke, Patrick W.
    Martinelli, Giovanni
    Gastaud, Lauris
    Thomas, Xavier
    Altman, Jessica K.
    Mendez, Lourdes M.
    de la Fuente, Adolfo
    Todisco, Elisabetta
    Gaidano, Gianluca
    Curti, Antonio
    Boissel, Nicolas
    Recher, Christian
    Schliemann, Christoph
    Konopleva, Marina
    Sallman, David A.
    Torres, Laura
    Marcucci, Guido
    Kantarjian, Hagop
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Sweet, Kendra
    BLOOD, 2021, 138
  • [45] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [46] TRIAL IN PROGRESS: A PHASE 1B STUDY OF ALRIZOMADLIN, ALONE OR PLUS 5-AZACITIDINE OR CYTARABINE, IN PTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND RELAPSED HIGHER-RISK MYELODYSPLASTIC SYNDROME
    Zhai, Yifan
    Wang, Jianxiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A478 - A478
  • [47] Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes (vol 28, pg 2253, 2010)
    Ganetzky, Rebecca
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3098 - 3098
  • [48] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Finelli, Carlo
    Giagounidis, Aristoteles
    Schoch, Robert
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Bennett, John M.
    Byrd, John
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    LANCET ONCOLOGY, 2009, 10 (03): : 223 - 232
  • [49] Electronic telemonitoring of patient-reported outcomes (PRO) in patients with myelodysplastic syndrome - a pilot study
    Luehring, A.
    Kuenstner, P.
    Tipelius, S.
    Rumpold, G.
    Stauder, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 134 - 135
  • [50] EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Conkling, P.
    Cogle, C. R.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Beach, C.
    Skikne, B. S.
    HAEMATOLOGICA, 2015, 100 : 239 - 239
12345